Table 2.
| os | Response | Co-occurring genetic alterations | |||||
|---|---|---|---|---|---|---|---|
| DNMT3A (12/91) | NPM1 (11/91) | WT1 (6/91) | CBF (18/91) | MLL translocation (7/91) | Complex Karyotype | ||
| 1250 | 1 | R882H | FS | WT | WT | WT | WT |
| 552 | 1 | G543C | WT | WT | WT | WT | WT |
| 1208 | 3 | WT | WT | FS (303) | WT | WT | WT |
| 2172 | 1 | WT | WT | WT | Inv16 | WT | WT |
| 1429 | 1 | WT | WT | WT | WT | WT | WT |
| 310 | 1 | WT | WT | WT | WT | t(11;19) | Complex |
Dfs = disease free survival, efs = event free survival, os = overall survival (0=alive, 1=deceased). Response (1=complete remission, 3 = No Change/Stable, 8 = unevaluated, -1 = unknown/missing). The number of patients with a given mutation in the 91 patient cohort are shown in parentheses.